



miRNA Therapeutics Against Cancer

Guest Editor:

Prof. Dr. Yukihiro Akao

United Graduate School of Drug
Discovery and Medical
Information Sciences, Gifu
University, 1-1 Yanagido, Gifu
501-1193, Japan

Deadline for manuscript
submissions:

closed (31 October 2020)

Message from the Guest Editor

Dear Colleagues,

Molecular target drugs against cancer induce tolerance by activating the alternative signal transduction pathways and developing genetic aberrations. MicroRNA (miRNA) is a group of small non-coding RNA that regulates gene expression at the translation step. MicroRNA targets every gene and depresses the growth-related signal pathways by silencing plural key genes involved in the signal pathways and systems. Accumulating evidence shows that dysregulated expression of tumor-suppressor (TS) miRNA contributes to carcinogenesis. The replacement of TS miRNA into cancer cells is a promising therapeutic because of its effect on tumor cell-specific and fewer resulting occurrences of tolerance. We will welcome papers discussing issues from miRNA medicine.

Prof. Dr. Yukihiro Akao
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)